Sanofi and the Curie Institute have agreed to cooperate in the search for new therapeutic targets for ovarian cancer using next-generation sequencing, reverse-phase protein analysis and patient-derived xenografts. The three-year collaboration seeks "to gain a better understanding of the molecular alterations that characterize many types of ovarian cancer, thereby enabling effective new drugs to be designed," the partners said.

Related Summaries